Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE In overall, besides implicating ERBB2 as an important therapeutic target under neo-adjuvant or adjuvant settings, we present the first evidence that the presence of KRAS mutations may preclude gallbladder cancer patients to respond to anti-EGFR treatment, similar to a clinical algorithm commonly practiced to opt for anti-EGFR treatment in colorectal cancer. 30304546

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE KRAS mutations were detected in 43% of 223 patients with metastatic CRC who were treated at the Ottawa Hospital. 31547963

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE We used mixed effect model to test for center-related heterogeneity (CRH) in recommendation, from the oldest to the more recent: (1) at least 12 lymph nodes analysed for stage II, (2) the prescription of adjuvant chemotherapy stage III and (3) the assessment of CRC molecular phenotype regarding KRAS status for stage IV. 30447905

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE We proved that some miR-425-5p targeted genes are involved in EGFR tyrosine kinase inhibitor resistance pathway, suggesting that therapies based on miR-425-5p may have strong potential in targeting KRAS-driven CRC. 31673240

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE APC and TP53 mutations were less frequent in MC compared to those in TCGA-CON (p < 0.001 and 0.003, respectively) whereas KRAS mutation was prevalent (p = 0.041). 31400926

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The current study investigated the anti-proliferative effect of quercetin on CRC cells harboring mutant or wild-type KRAS. 30203888

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE Inverse correlations between the expression levels of MYC, SUZ12, and KRAS and that of miR-487b exist in vitro and in CRC patient tissue specimens. 30791232

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue. 31207216

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Studies that reported the association of KRAS mutation with CRC clinical features and prognosis in databases were searched prior to 2018. 30917791

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Our findings provide a novel explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. 30353166

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE In the present study, we showed that RAGE has direct association with K-Ras following HMGB1 exposure in colorectal cancer (CRC) cells. 30456802

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 AlteredExpression BEFREE Colorectal cancer (CRC) is categorized by alteration of vital pathways such as β-catenin (CTNNB1) mutations, WNT signaling activation, tumor protein 53 (TP53) inactivation, BRAF, Adenomatous polyposis coli (APC) inactivation, KRAS, dysregulation of epithelial to mesenchymal transition (EMT) genes, MYC amplification, etc. 31699039

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE However, only a minority felt prepared to perform the following investigations: polyposis screening (34%), hereditary pancreatitis screening (30%), testing for Lynch yndrome (33%) and KRAS testing for colorectal cancer (20%).Most respondents would support holding dedicated training days on genomic medicine (83%), formal training provisions for the mainstreaming of genomic testing (64%), an update to the UK gastroenterology specialty training curriculum and examinations (57%) and better-defined referral pathways for local genomic services (91%). 31640999

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Particularly relevant in CRC are the activating mutations in the oncogene PIK3CA that frequently occur in concomitancy with KRAS and BRAF mutations and that lead to deregulation of the major signalling pathways PI3K and MAPK, downstream of EGFR. 30623365

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE We conducted a systematic review and meta-analysis of the additive effect of biologic agents to adjuvant chemotherapy on survival in colorectal cancer (all comers and subpopulations defined by microsatellite instability, BRAF and KRAS status, and stage). 30782542

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE As a result, a classification model built with methylation of SDC2 and SFRP2, KRAS mutations and hemoglobin showed a sensitivity of 91.4% for colorectal cancer and 60% for adenoma with the specificity of 86.1%. 31456088

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer. 30568222

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE We found that HER2 amplification is rare and poorly associated to IHC overexpression in extracolonic and extragastric GIT cancers; however in KRAS wild type colorectal cancers, which fail conventional treatment, HER2 IHC may be useful and should be considered. 31221175

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE We found KRAS exon 2 and BRAF<sup>V600E</sup> mutation rates were 37.7 and 2.8% in CRC patients. 30414169

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Enriching B-form of ctDNA with PI polyamides significantly improved the assay sensitivity in detecting KRAS mutations in non-metastatic CRC patient samples. 31383871

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. 31147600

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE KRAS is detected in 30%-50% of colorectal cancer (CRC) and BRAF mutations are found in 10% of CRC. 31519714

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE We detected a significantly low incidence of BRAF mutation in adenomas (2%) and CRC (0.7%), and a relatively low incidence of KRAS mutation (24.9%) compared with that in other populations. 31690257

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Of the 363 patients in the initial cohort, 11(3.0%) harbored oncogenic fusions and were all mismatch repair-deficient colorectal carcinomas with hypermethylated MLH1 and wild-type BRAF and KRAS, comprising 55% (11/20) of this subgroup. 30723297

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The gene encoding the GTPase KRAS is frequently mutated in pancreatic, lung, and colorectal cancers. 30559287

2019